的药物动力学和生物利用度clemastine配方和苯丙醇胺单组分和组合。

文章的细节

引用

复制到剪贴板

Schran高频,Petryk L, Chang CT,奥康纳R, Gelbert MB

的药物动力学和生物利用度clemastine配方和苯丙醇胺单组分和组合。

中国新药杂志。1996年10月,36(10):911 - 22所示。

PubMed ID

8930778 (在PubMed

]

文摘

在健康男性志愿者进行研究(n = 171;年龄范围,19-49年;每个研究对象)22 - 27日检查以下几点:药物动力学和抗组织胺clemastine剂量比例;的影响共同服用苯丙醇胺和clemastine两种药物的药物代谢动力学;和clemastine片剂的生物利用度和组合平板电脑clemastine和缓释phenyl-propanolamine禁食和美联储的条件下在单剂管理和稳定状态。交叉使用的所有研究设计,随机药物治疗由一个7天分开,洗脱期单剂的研究和管理每6或12小时每7天治疗稳态的研究。单剂量口服后clemastine解决方案(1、2和4毫克),曲线下的面积(AUC)和最大浓度(Cmax)剂量比例。Clemastine显示初步减少吸收的程度,用口服生物利用度计算为39.2 + / - 12.4%。没有血管的药物是由分布的高容量分布(799 + / - 315 L)和低Cmax (0.577 + / - 0.252 ng / mL / mg)观察到4.77 + / - 2.26小时后管理,以及两相的血浆浓度下降。终端消除半衰期(t1/2) clemastine是21.3 + / - 11.6小时。 Steady-state concentrations of clemastine were consistent with linear pharmacokinetic processes, and clearance was unaffected by age in the range studied, or by race. Clemastine solution and tablets were bioequivalent, and food had no significant effect on rate and extent of absorption of clemastine. The 1- and 2-mg clemastine tablets showed proportional bioavailability. Coadministration of clemastine with phenylpropanolamine did not significantly influence the pharmacokinetics of clemastine or the AUC and elimination t1/2 of phenylpropanolamine, but reduced the rate of absorption of phenylpropanolamine. Combination tablets containing 1 mg or 2 mg of immediate-release clemastine plus 75 mg of sustained-release phenylpropanolamine for twice daily administration were bioequivalent to the separate components and showed no significant interaction with food.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Clemastine

药物靶点

药物	目标	类	生物	药理作用	行动
Clemastine	组胺H1受体	蛋白质	人类	是的	拮抗剂	细节